20/20 Biolabs, Inc. Common Stock (AIDX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -182.8%, revenue growth 36.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $2.05M |
| Revenue (TTM) | $0.0B |
| Net Margin | -182.8% |
| Return on Equity | -358.8% |
| Operating Margin (TTM) | -215.7% |
| Current Ratio | 1.99 |
| Interest Coverage | -6.3 |
| Revenue Growth (YoY) | 36.5% |
| EPS Growth (YoY) | 52.9% |
| EV / EBITDA | -0.8 |
| Price / Book | 4.96 |
| Price / Sales | 3.94 |
| Altman Z-Score | -12.92 (distress) |
| Industry P/E (Business Services) | 28.3 |
| Sector P/E (Technology) | 31.8 |
AIDX overview · AIDX earnings · AIDX KPIs · AIDX documents · AIDX ownership · AIDX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.